Piper Sandler Maintains Overweight on Cogent Biosciences, Maintains $22 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Christopher Raymond maintains an Overweight rating on Cogent Biosciences (NASDAQ:COGT) and keeps the $22 price target.
June 12, 2023 | 4:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler analyst Christopher Raymond maintains an Overweight rating on Cogent Biosciences and a $22 price target.
The news of Piper Sandler maintaining an Overweight rating on Cogent Biosciences and keeping the $22 price target is positive for the stock. This indicates that the analyst believes the stock has potential for growth in the short term. Investors may view this as a positive signal, which could lead to an increase in demand for the stock and potentially drive the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100